Glucagon-like peptide 1 recruits muscle microvasculature and improves Insulin's metabolic action in the presence of Insulin resistance

Diabetes

Volumn 63, Issue 8, 2014, Pages 2788-2799

  Chai, Weidong ^a   Zhang, Xingxing ^a,b   Barrett, Eugene J ^a   Liu, Zhenqi ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; DIET, HIGH-FAT; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84904968496     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1597     Document Type: Article

References (45)

1. Ferrannini E, Simonson DC, Katz L.D., et al. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 1988; 37:79-85
2. DeFronzo RA, Gunnarsson R, Björkman O, Olsson M., Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 1985; 76:149-155
3. Barrett EJ, Eggleston EM, Inyard A.C., et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia 2009; 52:752-764
4. Barrett EJ, Wang H, Upchurch C.T., Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab 2011; 301:E252-E263
5. Clark MG, Wallis MG, Barrett E.J., et al. Blood flow and muscle metabolism: a focus on insulin action. Am J Physiol Endocrinol Metab 2003; 284:E241-E258
6. Kubota T, Kubota N, Kumagai H., et al. Impaired insulin signaling in endo-thelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13:294-307
7. Inyard AC, Clerk LH, Vincent M.A., Barrett EJ. Contraction stimulates nitric oxide independent microvascular recruitment and increases muscle insulin uptake. Diabetes 2007; 56:2194-2200
8. Wang N, Chai W, Zhao L., Tao L, Cao W, Liu Z. Losartan increases muscle insulin delivery and rescues insulin's metabolic action during lipid infusion via microvascular recruitment. Am J Physiol Endocrinol Metab 2013; 304:E538-E545
9. Zhao L, Chai W, Fu Z., et al. Globular adiponectin enhances muscle insulin action via microvascular recruitment and increased insulin delivery. Circ Res 2013; 112:1263-1271
10. Chai W, Wang W, Dong Z., Cao W, Liu Z. Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo. Diabetes 2011; 60:2939-2946
11. Vincent MA, Barrett EJ, Lindner J.R., Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003; 285:E123-E129
12. Clerk LH, Vincent MA, Jahn L.A., Liu Z., Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006; 55:1436-1442
13. Wallis MG, Wheatley CM, Rattigan S, Barrett E.J., Clark ADH, Clark MG. Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 2002; 51:3492-3498
14. Liu Z. The vascular endothelium in diabetes and its potential as a therapeutic target. Rev Endocr Metab Disord 2013; 14:1-3
15. Barrett EJ, Liu Z. The endothelial cell: an "early responder" in the development of insulin resistance. Rev Endocr Metab Disord 2013; 14:21-27
16. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-165
17. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117:24-32
18. Ussher JR, Drucker DJ Cardiovascular biology of the incretin system. Endocr Rev 2012; 33:187-215
19. Yu M, Moreno C, Hoagland K.M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21:1125-1135
20. Basu A, Charkoudian N, Schrage W., Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-E1295
21. Nyström T., Gutniak MK, Zhang Q, et al Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215
22. Richter G, Feddersen O, Wagner U., Barth P, Göke R, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993; 265:L374-L381
23. Chai W, Dong Z, Wang N., et al. Glucagon-like peptide 1 recruits micro-vasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012; 61:888-896
24. Dong Z, Chai W, Wang W., et al. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab 2013; 304:E222-E228
25. Ayala JE, Bracy DP, James F.D., Julien BM, Wasserman DH, Drucker DJ. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 2009; 150:1155-1164
26. Zhao T, Parikh P, Bhashyam S., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317:1106-1113
27. Nikolaidis LA, Elahi D, Hentosz T., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110:955-961
28. Kielgast U, Krarup T, Holst J.J., Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011; 34: 1463-1468
29. Raman VS, Mason KJ, Rodriguez L.M., et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010; 33:1294-1296
30. Rother KI, Spain LM, Wesley R.A., et al. Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. Diabetes Care 2009; 32:2251-2257
31. Chai W, Wang W, Liu J., et al. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use. Hypertension 2010; 55:523-530
32. Yang D, Luo Z, Ma S., et al. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab 2010; 12:130-141
33. Inyard AC, Chong DG, Klibanov A.L., Barrett EJ. Muscle contraction, but not insulin, increases microvascular blood volume in the presence of free fatty acid-induced insulin resistance. Diabetes 2009; 58:2457-2463
34. Castillo C, Bogardus C, Bergman R., Thuillez P, Lillioja S. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J Clin Invest 1994; 93:10-16
35. Chiu JD, Richey JM, Harrison L.N., et al. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endo-thelium limits the time course of insulin to activate glucose disposal. Diabetes 2008; 57:828-835
36. Gromada J, Dissing S, Rorsman P. Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms. Br J Pharmacol 1996; 118:769-775
37. Baggio LL, Kim J-G, Drucker DJ. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 2004; 53 (Suppl. 3):S205-S214
38. Erdogdu Ö, Nathanson D, Sjöholm Å, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010; 325:26-35
39. Eringa EC, Stehouwer CDA, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletal muscle arterioles are mediated by ERK1/2 activation in endothelium. Am J Physiol Heart Circ Physiol 2004; 287:H2043-H2048
40. Eringa EC, Stehouwer CDA, Merlijn T, Westerhof N., Sipkema P. Physiological concentrations of insulin induce endothelin-mediated vasoconstriction during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc Res 2002; 56:464-471
41. Eringa EC, Stehouwer CDA, Walburg K, et al Physiological concentrations of insulin induce endothelin-dependent vasoconstriction of skeletal muscle resistance arteries in the presence of tumor necrosis factor-alpha dependence on c-Jun N-terminal kinase. Arterioscler Thromb Vasc Biol 2006; 26:274-280
42. Dresner A, Laurent D, Marcucci M., et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103:253-259
43. Yu C, Chen Y, Cline G.W., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277:50230-50236
44. Green BD, Hand KV, Dougan J.E., McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008; 478: 136-142
45. Ye J, Gao Z, Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007; 293:E1118-E1128